Key Stats for Regeneron Stock
- 52-Week Range: $476.5 to $821.1
- Current Price: $761.9
- Street High Target: $1,057
What Happened?
Regeneron Pharmaceuticals (REGN), a Tarrytown-based biopharmaceutical company that discovers and commercializes antibody-based medicines, is undergoing a fundamental portfolio transition as EYLEA HD, its higher-dose next-generation retinal injection, now generates nearly half of the company’s total anti-VEGF franchise revenue while trading at $761.85, well below its 52-week high of $821.11.
Just yesterday, the FDA approved EYLEA HD as the first injectable anti-VEGF treatment with dosing intervals up to 5 months for wet age-related macular degeneration and diabetic macular edema, a blinding eye disease affecting millions of Americans, with the prefilled syringe approval decision due in April 2026 that management expects will unlock practices where vial-based administration has limited adoption.
That commercial momentum is increasingly visible in the numbers: EYLEA HD posted $506M in Q4 2025 U.S. net sales, up 66% year-over-year, while Dupixent, the company’s blockbuster antibody co-developed with Sanofi that treats inflammatory diseases from eczema to COPD, delivered $4.9B in Q4 global net sales, up 32%, helping Regeneron beat the Q4 adjusted EPS consensus by $0.82 and generating $4.1B in full-year free cash flow.
Also on April 2, Regeneron announced a strategic collaboration with TriNetX, investing up to $200M for exclusive access to de-identified electronic health records covering 300 million patients, including 170 million in the U.S., to accelerate drug discovery and train AI for digital health applications.
Marion McCourt, Executive Vice President of Commercial, stated on the Q4 2025 earnings call that “EYLEA HD now has the broadest label and greatest dosing flexibility of any anti-VEGF medicine,” directly following the FDA’s November approval of monthly dosing and the RVO indication that expanded the drug’s addressable market by roughly 20%.
Regeneron enters the next three to five years with its Sanofi development balance of $600M expected to be fully reimbursed by mid-2026, unlocking the full profit share on Dupixent’s $17.8B annual revenue base, while at least four FDA decisions are expected in 2026 across three new molecular entities, and a first-half readout of the fianlimab plus Libtayo combination in first-line advanced melanoma represents a potential standard-of-care shift in a market where competing LAG-3 combinations have topped only 10 months of median progression-free survival.
Wall Street’s Take on REGN Stock
The April 2 EYLEA HD approval extending dosing intervals to 5 months, combined with the TriNetX collaboration and the imminent Sanofi development balance payoff, shifts REGN’s near-term earnings trajectory meaningfully higher, making the current price a mispricing of compounding cash flows rather than a reflection of fundamental weakness.
Dupixent, the company’s flagship antibody that treats nine inflammatory diseases and generated $17.8B in 2025 global net sales, directly drives the Sanofi payoff: with $600M remaining at year-end 2025, TIKR estimates $15.68B in 2026 revenue rising to $17.3B in 2027, supported by EYLEA HD’s prefilled syringe decision due in April and Dupixent’s COPD, CSU, and adjuvant CSCC launches still in early penetration.
Wall Street has grown increasingly constructive: 18 analysts carry a buy rating, 3 an outperform, 7 a hold, and 1 an underperform, with a mean price target of $873.24 implying 14.6% upside from $761.85, as analysts position around the Sanofi balance resolution and multiple pipeline readouts converging in 2026.
The analyst target spread runs from $730 on the low end to $1,057 on the high end, with the floor anchored to EYLEA 2mg biosimilar pressure intensifying in the second half of 2026 and the ceiling contingent on a positive fianlimab plus Libtayo readout in first-line advanced melanoma, expected in the first half.
What Does the Valuation Model Say?
The TIKR mid-case model targets $1,246.25 by December 2030, implying a 63.6% total return and 10.9% IRR, anchored to a 7.8% revenue CAGR and a net income margin recovery to 37.6%, justified by the Sanofi development balance unwinding, EYLEA HD prefilled syringe adoption, and cemdisiran’s myasthenia gravis launch expanding the revenue base.
At roughly 17x TIKR’s 2026 normalized EPS estimate of $44.88, REGN trades at a meaningful discount to its five-year historical forward P/E in the low-to-mid 20s, even as EPS is set to re-accelerate from 1.3% growth in 2026 to 17% in 2027 once the full Dupixent profit share flows unencumbered, making REGN stock undervalued relative to its own earnings history at comparable or stronger growth.
The TIKR model’s core assumption, a $1,246.25 mid-case target built on 10% EPS CAGR through 2030, is directly supported by the Sanofi development balance payoff expected by mid-2026 and the $4.1B in 2025 free cash flow that management has committed to deploying through buybacks and BD.
Management’s signal is clear: Ryan Crowe stated at the TD Cowen conference that “most of it, besides maybe Dupixent and EYLEA, is not reflected in the valuation,” pointing to 45 pipeline programs the market is effectively pricing at zero.
The primary risk is Dupixent biosimilar entry earlier than the March 2031 U.S. composition-of-matter patent date, which would compress the profit-share windfall the model depends on through 2030.
The fianlimab plus Libtayo progression-free survival readout in first-line advanced melanoma, expected in the first half of 2026, is the single event that most immediately tests whether REGN’s pipeline optionality deserves a higher multiple; a median PFS in the low-to-mid teens would confirm best-in-class potential.
Should You Invest in Regeneron Pharmaceuticals, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up REGN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Regeneron Pharmaceuticals, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze REGN stock on TIKR for Free →
